Job Placement · Biotech and Life Sciences · VP R&D / Clinical
Biotech VP of R&D/clinical placement on milestone billing, not contingency. VPs own the research organization's portfolio, budget and go or no-go calls to the board, really paid at the 316,850 90th percentile for natural sciences managers, not the 167,220 median. BEG fills the seat in 23 to 35 days from 22,640.
See your exact placement price - no call required
See pricing before you talk to anyone. No demo gate, no obligation, and no co-employment.
TL;DR
A VP of R&D/clinical owns the research or clinical organization's portfolio, budget, headcount plan, and go or no-go recommendations to the CEO and board, with directors as direct reports. BLS prices the natural sciences manager code at a 167,220 median, but this seat is really paid at the 316,850 90th percentile. BEG prices the search from 22,640.
Why This Search Stalls
Boards want a VP who has already delivered a readout or approval in the company's modality, but that person's equity is priced on a catalyst the board cannot buy forward, so an offer built on base salary alone does not move them.
How BEG Fills This Seat
BEG scopes the seat to portfolio-level ownership, sources against the 90th percentile this role actually pays, and pushes the board to structure the equity offer before a finalist walks away.
| Step | What it requires | Where it stalls |
|---|---|---|
| Scope the portfolio mandate | A job description for budget, headcount and go or no-go recommendations across the full research or clinical portfolio, with directors reporting in | Boards post the role at manager-level scope and median pay, then cannot explain why portfolio-level candidates do not apply |
| Source against the 90th percentile | A VP who has delivered a clinical readout or an approval in the company’s modality | That track record is priced at the 316,850 90th percentile for the code, not the 167,220 median the budget was built around |
| Structure the equity offer | An option grant and vesting schedule spelled out alongside base salary, not base salary alone | The finalist’s current equity is priced on a catalyst the board cannot buy forward, so a base-salary-only offer letter does not move them |
| Close before the next financing cycle | A board decision fast enough to beat the company’s own next round or readout | Without a fast decision, the search reopens after the next quarter’s financing and the finalist who did not resign is gone |
BLS says most general and operations managers hired from outside a company need prior supervisory or management experience in a related field, so BEG screens VP candidates on managed headcount and budget, not just scientific output.
Milestone Billing Against Contingency
BEG bills a fixed Tier V milestone fee, 22,640 to 27,168, staged against the search rather than a percentage of the hire's salary, so the fee does not track the base-versus-equity mix a VP-level offer has to solve for. A VP's pipeline record is read against CDER's 46 novel drug approvals in 2025 and CBER's 54 licensed cellular and gene therapy products, the base rates a candidate's track record is judged by before BEG even prices the search.
The VP R&D/Clinical Math
At the 167,220 median BLS reports for natural sciences managers, a 20 percent contingency fee runs 33,444, and BEG's Tier V fee of 22,640 to 27,168 is 68 to 81 percent of that figure, a modest 19 to 32 percent less (BLS). But this seat is actually paid at the 316,850 90th percentile, where a 20 percent fee runs 63,370, and BEG is 36 to 43 percent of that, well over half less. Against the 209,060 research and development median, BEG runs 54 to 65 percent of a 20 percent fee. BEG is cheaper than contingency at every benchmark, most sharply at the pay level this seat actually commands.
Contingency, BEG, or Temp
At the pay level this seat actually commands, the 90th percentile, BEG's fixed Tier V fee runs well under half of a 20 percent contingency fee.
| Model | Who employs | How you pay | Right when |
|---|---|---|---|
| Contingency recruiter | You, direct | A percentage of first-year salary, commonly 20 to 25 percent, due at start | An executive search where a fee tied to a high base and equity package is acceptable |
| BEG milestone placement | You, direct hire | A fixed Tier V fee of 22,640 to 27,168, billed in stages against the search | A VP-level hire actually paid near the 316,850 90th percentile, where BEG runs well under half of a 20 percent contingency fee |
| Staffing or temp agency | The agency, not you | An hourly bill rate with markup, for as long as the assignment runs | Interim executive coverage during a transition, not a permanent VP hire |
See every tier and role BEG places across the vertical on the hub.
FAQ
The VP owns the research or clinical organization’s portfolio, budget, headcount plan, and go or no-go recommendations to the CEO and board, with directors as direct reports. A director who owns one program does not carry that portfolio-wide scope.
Boards want a VP who has already delivered a clinical readout or an FDA approval in the company’s modality, and that candidate’s current equity is priced on a catalyst the board cannot buy forward. An offer letter built on base salary alone, without a clear option grant and vesting schedule, does not move a finalist who has not resigned.
BLS prices the natural sciences manager code at a 167,220 median, but a VP with a real modality track record is usually paid closer to the 316,850 90th percentile for that code.
Yes, though the size of the gap depends on the benchmark. At the 167,220 median, BEG runs 19 to 32 percent cheaper. At the 316,850 90th percentile, the pay level this seat actually commands, BEG runs 57 to 64 percent cheaper, well over half.
BEG bills a fixed Tier V milestone fee of 22,640 to 27,168 for this role, staged against the search and unaffected by how large the base-plus-equity package ends up being.
No. BEG places VPs of R&D/clinical as your direct, permanent employees on milestone billing, not as interim executives.
BEG averages 23 to 35 days to fill an active VP search, with an 86 percent fill rate on searches it runs.
BLS says most general and operations managers hired from outside a company need prior supervisory or management experience in a related field, and that natural sciences manager growth tracks the scientists the role supervises, itself projected to grow faster than average.
Equity. BLS notes total executive compensation often includes stock options and bonuses beyond salary, and OEWS wage data exclude the self-employed, so no published wage figure shows what a candidate is actually giving up by moving.
Biochemists and biophysicists, medical scientists and biological technicians are all projected to grow much faster than average through 2035, 12, 13 and 7 percent respectively, so a VP’s own hiring plan for the team below them competes for the same people every other sponsor wants.
FDA’s September 2025 E6(R3) guidance clarifies sponsor responsibilities and advances risk-based quality management, and a drug made outside CGMP is legally adulterated regardless of product defect, two exposures this seat signs for across the whole portfolio. CDER’s 46 novel drug approvals in 2025 and CBER’s 54 licensed cellular and gene therapy products are the base rates a VP’s own pipeline record is measured against.
A director owns one program’s studies and submissions. A VP owns the full portfolio, budget and headcount plan with directors reporting in. A chief scientific officer owns the scientific strategy and external credibility for the whole company, one level above the VP.
Compare this seat with the director of clinical / regulatory role below it, or the chief scientific officer seat above it. Every biotech role BEG places is on the Biotech and Life Sciences hub.
More Biotech and Life Sciences placement
Ready?
Answer a few questions, get your exact number in about 90 seconds. No call required, no commitment.
See your exact placement price - no call required
